Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER-2 Positive Breast Cancer: A Collaborative Study of RTOG and KROG

ID Number 09-0762-00003

Principal Investigator(s)
Sheryl Green

Department(s) or Division(s)
Radiation Oncology


The purpose of this study is to compare the effects of adding lapatinib to standard whole brain radiation therapy (WBRT) on you and your cancer. The study will try to find out whether WBRT or lapatinib plus WBRT is better at safely improving tumor control. In this study, you will receive either lapatinib plus WBRT or WBRT alone.

Lapatinib is a drug that has been approved by the FDA for patients with progressive HER2-positive metastatic breast cancer. However, the combination of brain radiation and lapatinib for the treatment of brain metastases is experimental. The combination is being tested because lapatinib was found to improve the effectiveness of radiation therapy in the laboratory. An early study in patients showed that brain radiation and lapatinib can be combined safely.

You will receive the whole brain radiation therapy regardless of participating in the study.

You may qualify to take part in this research study because you have HER2-positive breast cancer that has spread to your brain.

Contact Information
Monika Anand
(212) 824-7501

Recruiting Patients: Yes